SU-E-T-01: Tumor Control Probability Models Derived Using Machine Learning for Head and Neck and Lung Tumors including a New Metric, Total Clonogen Survival (TCS)

2011 ◽  
Vol 38 (6Part10) ◽  
pp. 3485-3485
Author(s):  
J Oh ◽  
A Zuniga ◽  
W Thorstad ◽  
J Bradley ◽  
J Deasy
Keyword(s):  
Machine Learning ◽  
Head And Neck ◽  
Lung Tumors ◽  
Tumor Control ◽  
Tumor Control Probability ◽  
Probability Models

scholarly journals Automated Non-Coplanar VMAT for Dose Escalation in Recurrent Head and Neck Cancer Patients

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1910
Author(s):  
Kaley Woods ◽  
Robert K. Chin ◽  
Kiri A. Cook ◽  
Ke Sheng ◽  
Amar U. Kishan ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Dose Escalation ◽  
Volumetric Modulated Arc Therapy ◽  
Normal Tissue Complication Probability ◽  
Tumor Control ◽  
Tumor Control Probability ◽  
Increased Risk ◽  
Recurrent Head

This study evaluates the potential for tumor dose escalation in recurrent head and neck cancer (rHNC) patients with automated non-coplanar volumetric modulated arc therapy (VMAT) stereotactic body radiation therapy (SBRT) planning (HyperArc). Twenty rHNC patients are planned with conventional VMAT SBRT to 40 Gy while minimizing organ-at-risk (OAR) doses. They are then re-planned with the HyperArc technique to match these minimal OAR doses while escalating the target dose as high as possible. Then, we compare the dosimetry, tumor control probability (TCP), and normal tissue complication probability (NTCP) for the two plan types. Our results show that the HyperArc technique significantly increases the mean planning target volume (PTV) and gross tumor volume (GTV) doses by 10.8 ± 4.4 Gy (25%) and 11.5 ± 5.1 Gy (26%) on average, respectively. There are no clinically significant differences in OAR doses, with maximum dose differences of <2 Gy on average. The average TCP is 23% (± 21%) higher for HyperArc than conventional plans, with no significant differences in NTCP for the brainstem, cord, mandible, or larynx. HyperArc can achieve significant tumor dose escalation while maintaining minimal OAR doses in the head and neck—potentially enabling improved local control for rHNC SBRT patients without increased risk of treatment-related toxicities.

Field size reduction enables Iso-NTCP escalation of tumor control probability for irradiation of lung tumors

2001 ◽  
Vol 51 (5) ◽  
pp. 1290-1298 ◽  
Author(s):  
Martijn Engelsman ◽  
Peter Remeijer ◽  
Marcel van Herk ◽  
Joos V. Lebesque ◽  
Ben.J. Mijnheer ◽  
...  
Keyword(s):  
Lung Tumors ◽  
Size Reduction ◽  
Field Size ◽  
Tumor Control ◽  
Tumor Control Probability

scholarly journals Thyroid Dose and Hypothyroidism as a Result of Radiation Therapy for Head and Neck Malignancies and Brain Tumors in Iran

2020 ◽  
Author(s):  
Samira Yazdani ◽  
Fathollah Bouzarjomehri ◽  
Eric Slessinger
Keyword(s):  
Radiation Therapy ◽  
Head And Neck ◽  
Absorbed Dose ◽  
In Vivo Dosimetry ◽  
Tumor Control ◽  
Average Dose ◽  
Thyroid Function Tests ◽  
X Rays ◽  
Tumor Control Probability ◽  
Prescription Dose

Purpose: Radiation Therapy has a fundamental role in the treatment of cancer. Achieving Tumor Control Probability (TCP), while avoiding normal tissue complication is the goal of this treatment modality. The sensitivity of the thyroid gland to radiation increases the risk of developing secondary thyroid cancer and hypothyroidism. Materials and Methods: The average dose to the thyroid from head and neck irradiation was measured using in vivo dosimetry (Thermolumincsence Dosimetry). The Radiotherapy technique was given using 6 MV x-rays from an Elekta compact linear accelerator and conformal technique delivered 1.8 to 2.0 Gy over 5 sequential days per week. Results: The average absorbed dose to the thyroid from head and neck radiotherapy was 4.4% of the prescription dose and from whole brain radiotherapy was 0.7% of the prescription dose. Thyroid Stimulating Hormone (TSH) levels were determined in 30 patients before and after completion of radiation therapy. The average concentration of TSH increased from 0.88 +/- 0.55 (pre-radiotherapy) to 1.7 +/- 0.66 (post-radiotherapy), (p < 0.05). Conclusion: Thyroid absorbed dose was less than the threshold dose for patients who received radiotherapy to the head and neck based on thyroid function tests

Sign in / Sign up

Export Citation Format

Share Document